Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.13
(-62.83%)
USD 0.13
(-62.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -58.49 Million AUD | -12.72% |
| 2023 | -51.89 Million AUD | -32.52% |
| 2022 | -39.15 Million AUD | -15.01% |
| 2021 | -34.04 Million AUD | -182.53% |
| 2020 | -16.88 Million AUD | -140.3% |
| 2019 | -5.01 Million AUD | 43.82% |
| 2018 | -8.92 Million AUD | -45.76% |
| 2017 | -4.28 Million AUD | -41.81% |
| 2016 | -4.31 Million AUD | -59008.55% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -7.44 Million AUD | 70.26% |
| 2024 Q2 | -49.82 Million AUD | 0.0% |
| 2024 Q1 | -25.03 Million AUD | -83.75% |
| 2024 Q4 | -7.44 Million AUD | 0.0% |
| 2024 FY | - AUD | -24.0% |
| 2023 Q2 | -32.21 Million AUD | -97.17% |
| 2023 Q4 | -26.84 Million AUD | -99.44% |
| 2023 Q1 | -16.34 Million AUD | 16.88% |
| 2023 FY | - AUD | -32.52% |
| 2023 Q3 | -13.45 Million AUD | 58.22% |
| 2022 Q2 | -27.15 Million AUD | -96.96% |
| 2022 Q4 | -19.65 Million AUD | -95.05% |
| 2022 FY | - AUD | -15.01% |
| 2022 Q3 | -10.07 Million AUD | 62.89% |
| 2022 Q1 | -13.78 Million AUD | 35.53% |
| 2021 Q4 | -21.39 Million AUD | -93.02% |
| 2021 FY | - AUD | -182.53% |
| 2021 Q1 | -10.43 Million AUD | -75.84% |
| 2021 Q2 | -20.74 Million AUD | -98.85% |
| 2021 Q3 | -11.08 Million AUD | 46.58% |
| 2020 Q3 | -5.93 Million AUD | -136.5% |
| 2020 FY | - AUD | -140.3% |
| 2020 Q2 | -2.5 Million AUD | 0.0% |
| 2020 Q1 | -2.5 Million AUD | -10.17% |
| 2020 Q4 | -5.93 Million AUD | 0.0% |
| 2019 Q4 | -2.27 Million AUD | 0.0% |
| 2019 Q1 | -2.19 Million AUD | -65.15% |
| 2019 Q2 | -2.19 Million AUD | 0.0% |
| 2019 Q3 | -2.27 Million AUD | -3.53% |
| 2019 FY | - AUD | 43.82% |
| 2018 Q3 | -1.33 Million AUD | 25.31% |
| 2018 FY | - AUD | -45.76% |
| 2018 Q4 | -1.33 Million AUD | -0.02% |
| 2018 Q2 | -1.78 Million AUD | 0.0% |
| 2018 Q1 | -1.78 Million AUD | -141.8% |
| 2017 Q3 | -740.69 Thousand AUD | 47.42% |
| 2017 Q2 | -1.4 Million AUD | 0.0% |
| 2017 Q1 | -1.4 Million AUD | -75.7% |
| 2017 FY | - AUD | -41.81% |
| 2017 Q4 | -737.17 Thousand AUD | 0.48% |
| 2016 Q1 | -711.03 Thousand AUD | -48404.01% |
| 2016 Q3 | -801.69 Thousand AUD | -12.75% |
| 2016 Q4 | -801.69 Thousand AUD | 0.0% |
| 2016 FY | - AUD | -59008.55% |
| 2016 Q2 | -711.03 Thousand AUD | 0.0% |
| 2015 Q2 | 2476.00 AUD | 0.04% |
| 2015 Q4 | 1472.00 AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2015 Q1 | 2475.00 AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.74 Million USD | -3242.407% |
| Skye Bioscience, Inc. | -13.54 Million USD | -331.754% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 162.2% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 11189.955% |
| Qrons Inc. | -40.08 Thousand USD | -145834.687% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | -674.356% |
| CSL Limited | 4.78 Billion USD | 101.221% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -236.742% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -1405.851% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -6142.825% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -5.698% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -15828.305% |
| Rebus Holdings, Inc. | -951 Thousand USD | -6050.587% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -9149.135% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -268.576% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 17.659% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -886.557% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -24358.324% |
| SQZ Biotechnologies Company | -64.14 Million USD | 8.807% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -2111.882% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3707.957% |
| Mesoblast Limited | -62.38 Million USD | 6.247% |
| Marizyme, Inc. | -34.28 Million USD | -70.623% |
| Genus plc | 73.7 Million USD | 179.365% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -784.7% |
| Pharming Group N.V. | 9.87 Million USD | 692.205% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -3832.473% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1549.059% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -566.804% |
| ContraFect Corporation | -64.99 Million USD | 10.011% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -1192.301% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -4072.617% |
| IMV Inc. | -35.52 Million USD | -64.658% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -2417.066% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -11190.905% |
| ONE Bio Corp. | 13.61 Million USD | 529.677% |
| Accustem Sciences Inc. | -3.74 Million USD | -1461.28% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -21.285% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -4516.1% |
| Q BioMed Inc. | -617.62 Thousand USD | -9370.439% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1737.516% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2460.401% |
| Biomind Labs Inc. | -1.03 Million USD | -5553.873% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -47.57% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -1922.32% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -716.783% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 870000.089% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -233868.328% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -2237.849% |
| GB Sciences, Inc. | -1.41 Million USD | -4019.494% |
| Alpha Cognition Inc. | -9.7 Million USD | -502.663% |
| HST Global, Inc. | -5303.00 USD | -1102899.849% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -2743.563% |
| Halberd Corporation | -74.27 Thousand USD | -78646.459% |
| Enzolytics Inc. | -2.12 Million USD | -2656.422% |
| Agentix Corp. | -1.37 Million USD | -4164.03% |
| Resverlogix Corp. | -11.74 Million USD | -398.144% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1809.624% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 72.923% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 4906.252% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 760.644% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -3802.318% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 15539.622% |
| AVAX Technologies, Inc. | -6.11 Million USD | -856.903% |
| Zenith Capital Corp. | -8.6 Million USD | -579.666% |
| Genscript Biotech Corporation | -248.71 Million USD | 76.483% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -335656.168% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -2290.886% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -33129.538% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -2945.018% |
| Kadimastem Ltd | -2.62 Million USD | -2128.795% |
| Helix BioMedix, Inc. | -1.04 Million USD | -5490.31% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -32200.363% |
| LadRx Corporation | 412.28 Thousand USD | 14287.362% |
| Cell Source, Inc. | -4.27 Million USD | -1269.028% |
| Regen BioPharma, Inc. | 1.46 Million USD | 4090.03% |
| NovAccess Global Inc. | -1.03 Million USD | -5552.518% |
| Affymax, Inc. | -14.29 Million USD | -309.179% |
| Itoco Inc. | -1.86 Million USD | -3029.601% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -15308.061% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -5141.226% |
| Mobile Lads Corp. | -2.24 Million USD | -2509.903% |
| CytoDyn Inc. | -18.02 Million USD | -224.433% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -73913.441% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -478206.337% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -11943.387% |
| SYBLEU INC | -141.57 Thousand USD | -41216.429% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -5407.677% |
| International Stem Cell Corporation | 202 Thousand USD | 29056.476% |
| Bioxytran, Inc. | -3.82 Million USD | -1431.147% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -111017.177% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -2275.861% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -63.071% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -129882.404% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -2036.307% |
| Neutra Corp. | -181.24 Thousand USD | -32172.028% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -190.154% |
| PureTech Health plc | -11.62 Million USD | -403.071% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -190.174% |
| IXICO plc | -707 Thousand USD | -8173.279% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -661.12% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -20.986% |
| CSL Limited | 4.73 Billion USD | 101.236% |
| Cellectis S.A. | -92.63 Million USD | 36.858% |